UiPath (NYSE:PATH) Given New $15.00 Price Target at Morgan Stanley

UiPath (NYSE:PATH – Free Report) had its price objective trimmed by Morgan Stanley from $25.00 to $15.00 in a report published on Thursday morning, Benzinga reports. The firm currently has an equal weight rating on the healthcare company’s stock. A number of other brokerages have also issued reports on PATH. William Blair lowered shares of […]

Leave a Reply

Your email address will not be published.

Previous post Hargreaves Lansdown plc (OTCMKTS:HRGLF) Short Interest Update
Next post The cars of Beijing, China